Escitalopram Efficacy in Depression A Cross-Ethnicity Examination of the Serotonin Transporter Promoter Polymorphism
Chad A Bousman, Jerome Sarris, Eun-Soo Won, Hun-Soo Chang, Ajeet Singh, Hwa-Young Lee, Byung-Joo Ham, Chay-Hoon Tan, Min-Soo Lee, Chee H Ng
Journal of Clinical Psychopharmacology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2014
Current evidence suggests that polymorphism in the serotonin transporter gene (5-HTTLPR) predicts antidepressant efficacy in whites but less so in Asians. However, it is not clear whether this effect can be observed for specific types of antidepressant drugs. White (n = 47) and Korean (n = 118) participants with major depressive disorder were treated with escitalopram and assessed over 8 weeks. Among those with the l/l but not l/s or s/s genotypes, whites had greater depression score reductions, response rates, and remission rates compared with Koreans. Our results suggest that 5-HTTLPR predicts escitalopram efficacy in an ethnicity-dependent manner.
This investigator-initiated study was partly supported by an unrestricted research grant from H. Lundbeck A/S (at the site in Australia) and Changi General Hospital (at the site in Singapore). Courier of samples to Australia was facilitated by Quest Laboratories Pte Ltd. Escitalopram was sourced from H Lundbeck A/S.